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Introduction

Pathogenesis

Management

 Headaches, esp. Migraines have been extensively
reported in Antiphospholipid syndrome (APS)/
Antiphospholipid antibodies (aPL)-positive patients.
 APS associated headaches are often untreatable, poorly
responding to analgesics or narcotics and occur for
years before the diagnosis of APS. (1)
 Many
therapeutic
agents/strategies
such
as
hydroxychloroquine, B-cell inhibition, complement
inhibition and peptide therapy have been proposed to
manage thrombotic APS.
 Heparin followed by Long-term anticoagulation with
warfarin remains the cornerstone of treatment. (2)

 Alteration in platelet function during a migraine attack
with the binding of aPL on platelet membrane
phospholipids,
namely
phosphatidylserine,
phosphatidylcholine, and sphingomyelin, leads to
Platelet activation. (3)
 The lipid composition of platelet plasma membrane is
abnormal in migraine patients. An increase in
membrane
cholesterol-to-phospholipid
ratio
is
associated with platelet activation. (4)
 LA may be involved in migraine pathogenesis by
interacting with neuronal phospholipids such as
sphingomyelin. (5)
 Presence of aCL (Anticardiolipin) IgM or LA (Lupus
Anticoagulant) was significantly associated with
migraine in PAPS (Primary APS) patients. (6)

 One of the most prominent clinical considerations is the
complete resolution of headaches after anticoagulation
with heparin or warfarin for thrombosis treatment.
 A 2- to 3-week therapeutic trial of low molecular weight
(LMW) heparin has been used in many APS cases
where severe headaches were prominent.
 Multiple studies reported that heparin therapy reduced
the frequency and severity of migraine attacks. (7, 8)

Case Report
 36-year-old Caucasian female with past medical history
significant for Tumid Lupus Erythematosus treated with
Hydroxychloroquine, Fibromyalgia and remote history
of Irritable Bowel Syndrome with no history of
Thrombosis, miscarriages, fetal death or preeclampsia.
 Presented with Severe headaches, 8/10 intensity for the
last 4 years. Headaches reported as migraines with
stabbing pain, occasionally localizing to right side.
 Patient had undergone extensive workup by Neurology
as well as Rheumatology including a normal Lumbar
Puncture and multiple normal MRI brain. Blood work
showed Lupus Anticoagulant positivity.
 Various treatments for symptomatic Headaches without
any significant improvement were tried. The patient
was then started on Warfarin Therapy by Rheumatology
which significantly relieved the symptoms.
 Later, when warfarin was discontinued by the
neurologist, who the patient saw for a follow up, it
resulted in worsening of the headaches.
 The headaches resolved again on restarting the Warfarin
Therapy.

Imaging
 Patients with hemiplegic migraine or those with known
history of migraine presenting with signs of stroke may
demonstrate areas of infarction.
 Migraine sufferers with elevated aPL but without
hemiplegia or signs of infarction rarely show findings
on imaging studies such as computerized tomography
(CT), magnetic resonance imaging (MRI) or cerebral
angiogram.

Associated clinical features
 Many non-thrombotic neurologic diseases are related
to APS and may range from focal lesions to diffuse
dysfunction, part of which are migraine, cognitive and
memory deficits, extrapyramidal symptoms behavioral
and seizures.
 Authors suggest that aPL may be associated with
migraine that is commonly followed by an ischemic
stroke. (9)

Highlights
 Headaches and Migraines in particular are common in
APS and aPL-positive patients.
The pathogenesis of APS headaches is unclear, but it
could be related to Platelet dysfunction.
APS patients with severe refractory migraine show very
good response to Warfarin therapy with INR goal of
2.5-3.5 (9)
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